Click here to get full coverage on Replimune Group (REPL) Price Target Increased by 10.52% to 12.82 - Nasdaq

Replimune Group (REPL) Price Target Increased by 10.52% to 12.82  Nasdaq

Replimune Group (REPL) Price Target Increased by 10.52% to 12.82 - Nasdaq

Click here to get full coverage on Replimune (REPL) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action Pending - Hagens Berman - PR Newswire

Replimune (REPL) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action Pending - Hagens Berman  PR Newswire

Replimune (REPL) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action Pending - Hagens Berman - PR Newswire

Click here to get full coverage on Levi & Korsinsky Notifies Replimune Group, Inc. (REPL) Investors - The National Law Review

Levi & Korsinsky Notifies Replimune Group, Inc. (REPL) Investors  The National Law Review

Levi & Korsinsky Notifies Replimune Group, Inc. (REPL) Investors - The National Law Review

Click here to get full coverage on A Look at Replimune Group’s (REPL) Valuation Following Promising IGNYTE Phase 2 Melanoma Trial Results - Yahoo Finance

A Look at Replimune Group’s (REPL) Valuation Following Promising IGNYTE Phase 2 Melanoma Trial Results  Yahoo Finance

A Look at Replimune Group’s (REPL) Valuation Following Promising IGNYTE Phase 2 Melanoma Trial Results - Yahoo Finance

Click here to get full coverage on $REPL stock is up 16% today. Here's what we see in our data. - Quiver Quantitative

$REPL stock is up 16% today. Here's what we see in our data.  Quiver Quantitative

$REPL stock is up 16% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug - Zacks Investment Research

REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug  Zacks Investment Research

REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug - Zacks Investment Research

Click here to get full coverage on Here's Why Replimune Group (REPL) Stock Is Up Over 100% Today - Benzinga

Here's Why Replimune Group (REPL) Stock Is Up Over 100% Today  Benzinga

Here's Why Replimune Group (REPL) Stock Is Up Over 100% Today - Benzinga

Click here to get full coverage on REPLIMUNE GROUP, INC. (NASDAQ: REPL) SHAREHOLDER ALERT - GlobeNewswire

REPLIMUNE GROUP, INC. (NASDAQ: REPL) SHAREHOLDER ALERT  GlobeNewswire

REPLIMUNE GROUP, INC. (NASDAQ: REPL) SHAREHOLDER ALERT - GlobeNewswire

Click here to get full coverage on Replimune Group (REPL) Nosedives 39% as FDA Approval for Melanoma Treatment ‘Uncertain’ - Yahoo Finance

Replimune Group (REPL) Nosedives 39% as FDA Approval for Melanoma Treatment ‘Uncertain’  Yahoo Finance

Replimune Group (REPL) Nosedives 39% as FDA Approval for Melanoma Treatment ‘Uncertain’ - Yahoo Finance

Click here to get full coverage on Replimune Group (REPL) Price Target Increased by 48.75% to 10.84 - Nasdaq

Replimune Group (REPL) Price Target Increased by 48.75% to 10.84  Nasdaq

Replimune Group (REPL) Price Target Increased by 48.75% to 10.84 - Nasdaq

Click here to get full coverage on REPL 2-WEEK DEADLINE ALERT: Replimune (REPL) Faces Investor Lawsuit After FDA Blocks Cancer Drug Approval - Hagens Berman - PR Newswire

REPL 2-WEEK DEADLINE ALERT: Replimune (REPL) Faces Investor Lawsuit After FDA Blocks Cancer Drug Approval - Hagens Berman  PR Newswire

REPL 2-WEEK DEADLINE ALERT: Replimune (REPL) Faces Investor Lawsuit After FDA Blocks Cancer Drug Approval - Hagens Berman - PR Newswire

Click here to get full coverage on $REPL stock is down 9% today. Here's what we see in our data. - Quiver Quantitative

$REPL stock is down 9% today. Here's what we see in our data.  Quiver Quantitative

$REPL stock is down 9% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Replimune (REPL) Faces Securities Class Action Following Stock's Collapse Amid FDA's Rejection of Melanoma Drug - Hagens Berman - PR Newswire

Replimune (REPL) Faces Securities Class Action Following Stock's Collapse Amid FDA's Rejection of Melanoma Drug - Hagens Berman  PR Newswire

Replimune (REPL) Faces Securities Class Action Following Stock's Collapse Amid FDA's Rejection of Melanoma Drug - Hagens Berman - PR Newswire

Click here to get full coverage on REPL 6-DAY DEADLINE ALERT: Investor Lawsuit Targets Replimune (REPL) After FDA Deems RP1 Trial Inadequate - Hagens Berman - PR Newswire

REPL 6-DAY DEADLINE ALERT: Investor Lawsuit Targets Replimune (REPL) After FDA Deems RP1 Trial Inadequate - Hagens Berman  PR Newswire

REPL 6-DAY DEADLINE ALERT: Investor Lawsuit Targets Replimune (REPL) After FDA Deems RP1 Trial Inadequate - Hagens Berman - PR Newswire

Click here to get full coverage on REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm - PR Newswire

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm  PR Newswire

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm - PR Newswire

Click here to get full coverage on $REPL stock is down 14% today. Here's what we see in our data. - Quiver Quantitative

$REPL stock is down 14% today. Here's what we see in our data.  Quiver Quantitative

$REPL stock is down 14% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Replimune Group Inc. Stock (REPL) Opinions on FDA Drug Rejection - Nasdaq

Replimune Group Inc. Stock (REPL) Opinions on FDA Drug Rejection  Nasdaq

Replimune Group Inc. Stock (REPL) Opinions on FDA Drug Rejection - Nasdaq

Click here to get full coverage on JP Morgan Upgrades Replimune Group (REPL) - Nasdaq

JP Morgan Upgrades Replimune Group (REPL)  Nasdaq

JP Morgan Upgrades Replimune Group (REPL) - Nasdaq

Click here to get full coverage on Hill, Replimune CFO, sells $49k in REPL stock - Investing.com

Hill, Replimune CFO, sells $49k in REPL stock  Investing.com

Hill, Replimune CFO, sells $49k in REPL stock - Investing.com

Click here to get full coverage on New Analyst Forecast: $REPL Given $4.0 Price Target - Quiver Quantitative

New Analyst Forecast: $REPL Given $4.0 Price Target  Quiver Quantitative

New Analyst Forecast: $REPL Given $4.0 Price Target - Quiver Quantitative

Click here to get full coverage on Replimune Group (REPL): Valuation in Focus After FDA Setback and Investor Lawsuit Announcements - Yahoo Finance

Replimune Group (REPL): Valuation in Focus After FDA Setback and Investor Lawsuit Announcements  Yahoo Finance

Replimune Group (REPL): Valuation in Focus After FDA Setback and Investor Lawsuit Announcements - Yahoo Finance

Click here to get full coverage on 44% ORR in acral melanoma — Replimune RP1 + nivolumab; median DOR 11.9 months at ESMO 2025 - Stock Titan

44% ORR in acral melanoma — Replimune RP1 + nivolumab; median DOR 11.9 months at ESMO 2025  Stock Titan

44% ORR in acral melanoma — Replimune RP1 + nivolumab; median DOR 11.9 months at ESMO 2025 - Stock Titan

Click here to get full coverage on Why Is Replimune Stock (REPL) Up 105% Today? - TipRanks

Why Is Replimune Stock (REPL) Up 105% Today?  TipRanks

Why Is Replimune Stock (REPL) Up 105% Today? - TipRanks

Click here to get full coverage on Replimune (NASDAQ: REPL) posts 24.8‑month DoR with RP1+nivolumab in PD‑1‑failed melanoma - Stock Titan

Replimune (NASDAQ: REPL) posts 24.8‑month DoR with RP1+nivolumab in PD‑1‑failed melanoma  Stock Titan

Replimune (NASDAQ: REPL) posts 24.8‑month DoR with RP1+nivolumab in PD‑1‑failed melanoma - Stock Titan

Click here to get full coverage on Replimune, Sarepta, Capricor Stocks Surge: Analyst Says Vinay Prasad’s Exit From FDA Positive For Biopharma Sector - Stocktwits

Replimune, Sarepta, Capricor Stocks Surge: Analyst Says Vinay Prasad’s Exit From FDA Positive For Biopharma Sector  Stocktwits

Replimune, Sarepta, Capricor Stocks Surge: Analyst Says Vinay Prasad’s Exit From FDA Positive For Biopharma Sector - Stocktwits

Click here to get full coverage on REPL Stock News: Investors with Large Losses Should Contact Robbins LLP for Information About Leading the Replimune Group, Inc. Class Action Lawsuit - PR Newswire

REPL Stock News: Investors with Large Losses Should Contact Robbins LLP for Information About Leading the Replimune Group, Inc. Class Action Lawsuit  PR Newswire

REPL Stock News: Investors with Large Losses Should Contact Robbins LLP for Information About Leading the Replimune Group, Inc. Class Action Lawsuit - PR Newswire

Click here to get full coverage on Why Is Replimune Stock (NASDAQ:REPL) Exploding? - TipRanks

Why Is Replimune Stock (NASDAQ:REPL) Exploding?  TipRanks

Why Is Replimune Stock (NASDAQ:REPL) Exploding? - TipRanks

Click here to get full coverage on REPL STOCK NEWS: Replimune Group, Inc. (NASDAQ:REPL) is - GlobeNewswire

REPL STOCK NEWS: Replimune Group, Inc. (NASDAQ:REPL) is  GlobeNewswire

REPL STOCK NEWS: Replimune Group, Inc. (NASDAQ:REPL) is - GlobeNewswire

Click here to get full coverage on BMO Capital Upgrades Replimune Group (REPL) - Nasdaq

BMO Capital Upgrades Replimune Group (REPL)  Nasdaq

BMO Capital Upgrades Replimune Group (REPL) - Nasdaq

Click here to get full coverage on $REPL stock is up 13% today. Here's what we see in our data. - Nasdaq

$REPL stock is up 13% today. Here's what we see in our data.  Nasdaq

$REPL stock is up 13% today. Here's what we see in our data. - Nasdaq

Click here to get full coverage on PDUFA Apr 10, 2026: Replimune's BLA Resubmission for RP1 Accepted by FDA for Advanced Melanoma - Stock Titan

PDUFA Apr 10, 2026: Replimune's BLA Resubmission for RP1 Accepted by FDA for Advanced Melanoma  Stock Titan

PDUFA Apr 10, 2026: Replimune's BLA Resubmission for RP1 Accepted by FDA for Advanced Melanoma - Stock Titan

Click here to get full coverage on Replimune Group (REPL): Valuation Update After FDA Acceptance of RP1 Application Spurs Investor Optimism - simplywall.st

Replimune Group (REPL): Valuation Update After FDA Acceptance of RP1 Application Spurs Investor Optimism  simplywall.st

Replimune Group (REPL): Valuation Update After FDA Acceptance of RP1 Application Spurs Investor Optimism - simplywall.st

Click here to get full coverage on Replimune (REPL) Faces Investor Lawsuit Following 77% Stock Crash After FDA Rejects Key Drug - Hagens Berman - GlobeNewswire

Replimune (REPL) Faces Investor Lawsuit Following 77% Stock Crash After FDA Rejects Key Drug - Hagens Berman  GlobeNewswire

Replimune (REPL) Faces Investor Lawsuit Following 77% Stock Crash After FDA Rejects Key Drug - Hagens Berman - GlobeNewswire

Click here to get full coverage on Replimune: Acceptance Confirms Completeness, Not Approval (Rating Upgrade) - Seeking Alpha

Replimune: Acceptance Confirms Completeness, Not Approval (Rating Upgrade)  Seeking Alpha

Replimune: Acceptance Confirms Completeness, Not Approval (Rating Upgrade) - Seeking Alpha

Click here to get full coverage on FDA Denies Approval for Replimune's Advanced Melanoma Treatment: What's Behind the Rejection - Stock Titan

FDA Denies Approval for Replimune's Advanced Melanoma Treatment: What's Behind the Rejection  Stock Titan

FDA Denies Approval for Replimune's Advanced Melanoma Treatment: What's Behind the Rejection - Stock Titan

Click here to get full coverage on Replimune (REPL) Faces Securities Class Action Following - GlobeNewswire

Replimune (REPL) Faces Securities Class Action Following  GlobeNewswire

Replimune (REPL) Faces Securities Class Action Following - GlobeNewswire

Click here to get full coverage on REPL Stock: An Unexpected Surge or a Bubble?​ - StocksToTrade

REPL Stock: An Unexpected Surge or a Bubble?​  StocksToTrade

REPL Stock: An Unexpected Surge or a Bubble?​ - StocksToTrade

Click here to get full coverage on REPL DEADLINE: Replimune Group Investors Should Contact - GlobeNewswire

REPL DEADLINE: Replimune Group Investors Should Contact  GlobeNewswire

REPL DEADLINE: Replimune Group Investors Should Contact - GlobeNewswire

Click here to get full coverage on Biggest stock movers Thursday: INTC, NVO, ETNB, REPL, and more - Seeking Alpha

Biggest stock movers Thursday: INTC, NVO, ETNB, REPL, and more  Seeking Alpha

Biggest stock movers Thursday: INTC, NVO, ETNB, REPL, and more - Seeking Alpha

Click here to get full coverage on Is Replimune Group (NASDAQ:REPL) A Risky Investment? - simplywall.st

Is Replimune Group (NASDAQ:REPL) A Risky Investment?  simplywall.st

Is Replimune Group (NASDAQ:REPL) A Risky Investment? - simplywall.st

Click here to get full coverage on BREAKING: Replimune Shares Drop Over 40%; Investors Should - GlobeNewswire

BREAKING: Replimune Shares Drop Over 40%; Investors Should  GlobeNewswire

BREAKING: Replimune Shares Drop Over 40%; Investors Should - GlobeNewswire

Click here to get full coverage on REPL 3-DAY DEADLINE ALERT: Replimune (REPL) Shares Tank 45% - GlobeNewswire

REPL 3-DAY DEADLINE ALERT: Replimune (REPL) Shares Tank 45%  GlobeNewswire

REPL 3-DAY DEADLINE ALERT: Replimune (REPL) Shares Tank 45% - GlobeNewswire

Click here to get full coverage on Vibe Coding Something Useful with Repl.it - KDnuggets

Vibe Coding Something Useful with Repl.it  KDnuggets

Vibe Coding Something Useful with Repl.it - KDnuggets

Click here to get full coverage on Biotech Replimune's Advanced Melanoma Drug RP1 Faces Uncertain FDA Path Following Critical Meeting - Stock Titan

Biotech Replimune's Advanced Melanoma Drug RP1 Faces Uncertain FDA Path Following Critical Meeting  Stock Titan

Biotech Replimune's Advanced Melanoma Drug RP1 Faces Uncertain FDA Path Following Critical Meeting - Stock Titan

Click here to get full coverage on Replimune stock rises as Cantor Fitzgerald upgrades (REPL) - Seeking Alpha

Replimune stock rises as Cantor Fitzgerald upgrades (REPL)  Seeking Alpha

Replimune stock rises as Cantor Fitzgerald upgrades (REPL) - Seeking Alpha

Click here to get full coverage on Join the Replimune Group (REPL) Securities Fraud Lawsuit Investigation - Claim Depot

Join the Replimune Group (REPL) Securities Fraud Lawsuit Investigation  Claim Depot

Join the Replimune Group (REPL) Securities Fraud Lawsuit Investigation - Claim Depot

Click here to get full coverage on REPL CLASS ACTION ALERT: FDA Response Letter Leads to - GlobeNewswire

REPL CLASS ACTION ALERT: FDA Response Letter Leads to  GlobeNewswire

REPL CLASS ACTION ALERT: FDA Response Letter Leads to - GlobeNewswire

Click here to get full coverage on Replimune Group: The Prospects For FDA Approval After Rejection (REPL) - Seeking Alpha

Replimune Group: The Prospects For FDA Approval After Rejection (REPL)  Seeking Alpha

Replimune Group: The Prospects For FDA Approval After Rejection (REPL) - Seeking Alpha

Click here to get full coverage on REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm  PR Newswire

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire

Click here to get full coverage on Replimune Group Inc (REPL) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... - Yahoo Finance

Replimune Group Inc (REPL) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ...  Yahoo Finance

Replimune Group Inc (REPL) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... - Yahoo Finance

Click here to get full coverage on REPL Deadline: REPL Investors with Losses in Excess of $100K Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit Filed by The Rosen Law Firm - PR Newswire

REPL Deadline: REPL Investors with Losses in Excess of $100K Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit Filed by The Rosen Law Firm  PR Newswire

REPL Deadline: REPL Investors with Losses in Excess of $100K Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit Filed by The Rosen Law Firm - PR Newswire

Click here to get full coverage on Will FDA Progress Change Replimune Group's (REPL) Position in the Advanced Melanoma Treatment Market? - simplywall.st

Will FDA Progress Change Replimune Group's (REPL) Position in the Advanced Melanoma Treatment Market?  simplywall.st

Will FDA Progress Change Replimune Group's (REPL) Position in the Advanced Melanoma Treatment Market? - simplywall.st

Click here to get full coverage on INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL - PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL  PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL - PR Newswire

Click here to get full coverage on Wedbush Upgrades Replimune Group (REPL), Raises Price Target Sig - GuruFocus

Wedbush Upgrades Replimune Group (REPL), Raises Price Target Sig  GuruFocus

Wedbush Upgrades Replimune Group (REPL), Raises Price Target Sig - GuruFocus

Click here to get full coverage on REPL Stock Drops: A Closer Look - timothysykes.com

REPL Stock Drops: A Closer Look  timothysykes.com

REPL Stock Drops: A Closer Look - timothysykes.com

Click here to get full coverage on Replimune stock downgraded at J.P. Morgan (REPL:NASDAQ) - Seeking Alpha

Replimune stock downgraded at J.P. Morgan (REPL:NASDAQ)  Seeking Alpha

Replimune stock downgraded at J.P. Morgan (REPL:NASDAQ) - Seeking Alpha

Click here to get full coverage on REPL LAWSUIT REMINDER: Replimune Group, Inc. Investors with Losses are Reminded to Contact BFA Law by September 22 about Securities Fraud Class Action - Newsfile

REPL LAWSUIT REMINDER: Replimune Group, Inc. Investors with Losses are Reminded to Contact BFA Law by September 22 about Securities Fraud Class Action  Newsfile

REPL LAWSUIT REMINDER: Replimune Group, Inc. Investors with Losses are Reminded to Contact BFA Law by September 22 about Securities Fraud Class Action - Newsfile

Click here to get full coverage on Replimune: Further Uncertainty Of RP1 Warrants Move To 'Hold' Rating (NASDAQ:REPL) - Seeking Alpha

Replimune: Further Uncertainty Of RP1 Warrants Move To 'Hold' Rating (NASDAQ:REPL)  Seeking Alpha

Replimune: Further Uncertainty Of RP1 Warrants Move To 'Hold' Rating (NASDAQ:REPL) - Seeking Alpha

Click here to get full coverage on Replimune stock down after report on drug rejection (REPL) - Seeking Alpha

Replimune stock down after report on drug rejection (REPL)  Seeking Alpha

Replimune stock down after report on drug rejection (REPL) - Seeking Alpha

Click here to get full coverage on REPL Stock Rises on FDA's Priority Review for Melanoma Drug BLA - Yahoo Finance

REPL Stock Rises on FDA's Priority Review for Melanoma Drug BLA  Yahoo Finance

REPL Stock Rises on FDA's Priority Review for Melanoma Drug BLA - Yahoo Finance

Click here to get full coverage on Replimune Group: Analysts Are More Optimistic Than The Market (NASDAQ:REPL) - Seeking Alpha

Replimune Group: Analysts Are More Optimistic Than The Market (NASDAQ:REPL)  Seeking Alpha

Replimune Group: Analysts Are More Optimistic Than The Market (NASDAQ:REPL) - Seeking Alpha

Click here to get full coverage on Replimune (REPL) Sees Shares Skyrocket Following FDA Acceptance - GuruFocus

Replimune (REPL) Sees Shares Skyrocket Following FDA Acceptance  GuruFocus

Replimune (REPL) Sees Shares Skyrocket Following FDA Acceptance - GuruFocus

Click here to get full coverage on JPMorgan Boosts Replimune (REPL) Price Target Amid Approval Opti - GuruFocus

JPMorgan Boosts Replimune (REPL) Price Target Amid Approval Opti  GuruFocus

JPMorgan Boosts Replimune (REPL) Price Target Amid Approval Opti - GuruFocus

Click here to get full coverage on Noteworthy Monday Option Activity: UNH, REPL, CELC - Nasdaq

Noteworthy Monday Option Activity: UNH, REPL, CELC  Nasdaq

Noteworthy Monday Option Activity: UNH, REPL, CELC - Nasdaq

Click here to get full coverage on Replimune stock falls as FDA rejects lead drug (REPL:NASDAQ) - Seeking Alpha

Replimune stock falls as FDA rejects lead drug (REPL:NASDAQ)  Seeking Alpha

Replimune stock falls as FDA rejects lead drug (REPL:NASDAQ) - Seeking Alpha

Click here to get full coverage on $REPL stock is up 13% today. Here's what we see in our data. - Quiver Quantitative

$REPL stock is up 13% today. Here's what we see in our data.  Quiver Quantitative

$REPL stock is up 13% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Replimune's Melanoma Drug Hits FDA Roadblock: Q1 Losses Widen to $86.7M as Clinical Trials Advance - Stock Titan

Replimune's Melanoma Drug Hits FDA Roadblock: Q1 Losses Widen to $86.7M as Clinical Trials Advance  Stock Titan

REPL

Price Chart

Key Statistics

Technicals

About REPL

Latest News

Replimune Group (REPL) Price Target Increased by 10.52% to 12.82 - Nasdaq

Replimune (REPL) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action Pending - Hagens Berman - PR Newswire

Levi & Korsinsky Notifies Replimune Group, Inc. (REPL) Investors - The National Law Review

Advanced Charts

Top Gainers

Top Losers